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A Ab bs st tr ra ac ct t
This paper discusses the presentation I held at the symposium on genetics during the 4
th European Breast Cancer
Conference held in Hamburg in March 2004. 
Primarily, the goals and working methods of the advocacy group specialised in Hereditary Breast/Ovarian
Cancer of the Dutch Breast Cancer Patient Organisation known as BorstkankerVereniging Nederland (BVN) are
explained. Furthermore, some specific individual problems that mutation carriers might encounter before and
after BRCA1/2 susceptibility testing are discussed. These include: dilemmas in choosing preventive interventions,
dealing with the psychological impact of knowing you are a mutation carrier, dealing with the social implications
of being genetically at risk, an example of insurance discrimination. In addition, some controversial social and
ethical issues that are currently under debate are highlighted, such as the issue of the European patenting of
the breast cancer susceptibility genes BRCA1 and BRCA2. Since this topic could also become relevant for other
gene-related diseases, society as a whole has to consider the ethical and social implications related to the
patenting of human genes in general. Another ethical area of debate is the controversial issue of prenatal BRCA
testing and the choice of pregnancy termination. 
Finally, the Working Party pleads for the international co-operation and exchange of data and experience among
professionals as well as patients. It appears that professionals in different European countries tend to advise on
different risk management strategies and treatments and as such, the Working Party strongly advocates the
international standardisation of risk management and treatment of mutation carriers. In this respect, specific
attention should be given to a group that has had a non-informative or negative BRCA test result, because this
group is still considered to be at high risk to develop the disease. 
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T Th he e   W Wo or rk ki in ng g   P Pa ar rt ty y   o on n   h he er re ed di it ta ar ry y
b br re ea as st t/ /o ov va ar ri ia an n   c ca an nc ce er r: :   
g go oa al ls s   a an nd d   m me et th ho od ds s
The Working Party on hereditary breast/ovarian
cancer, which I am currently chairing, primarily
safeguards the interests of and offers support to
people whose lives are affected by hereditary breast
and ovarian cancer. The Working Party consists of
10 non-professional volunteers (mostly mutation
carriers and their relatives) and 4 professional
advisory members. The Working Party was originally
founded by the Rotterdam family cancer clinic of
Erasmus Medical Centre, but is now part of the BVN,H He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2004; 2(4) 200
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a nationwide Patient Organisation exclusively for
breast  cancer  patients,  with  more  than  5,000
members. 
R Ra ai is se e  a aw wa ar re en ne es ss s  a an nd d  g gi iv ve e  i in nf fo or rm ma at ti io on n
It is one of the main goals of the Working Party to
raise awareness on hereditary breast and ovarian
cancer among patients and their relatives, doctors,
nurses and other professionals, but also among the
general population. 
Providing information is also one of the main goals
and it is of course used as a tool in creating more
awareness. The Working Party specifically directs its
efforts to find healthy unaffected mutation carriers and
make them not only aware of their risks of developing
cancer, but also of the advantages of risk management
strategies that are offered to prevent them from
developing cancer. 
W Wo or rk ki in ng g  m me et th ho od ds s
Some examples of the methods of the Working
Party are: to spread information brochures and have
a monthly “walk-in consulting hour” in two major
clinics  in  Amsterdam  and  Rotterdam;  to  give
testimonials at conferences and hearings for patients
and professionals such as training courses for nurses;
to seek publicity via various media outlets which
focuses not only on specialised journals, but also on
well-known women’s weekly magazines; to co-operate
with  television  programmes  and  have  teaching
sessions with students. Furthermore, the Working Party
organises  informative  meetings,  workshops  and
symposia across the country: in 2002 the Working
Party organised a conference for mutation carriers
and their families which was attended by 250 people.
The Working Party advertises itself on the website of
the BVN but also has a specialised website on
hereditary  breast/ovarian  cancer  with  general
(accurate)  information,  contributions  from
professionals and links to relevant institutions and
other websites. We are also represented in and co-
operate with national and international organisations
with similar interests.
O Of ff fe er ri in ng g  s su up pp po or rt t
The Working Party also acts as a service-support
group and is involved in the helpline of the BVN. The
members of the Working Party aim, from their personal
point of view and using their own experience, to offer
emotional support to a wide range of people who face
hereditary breast and/or ovarian cancer. All these
individuals  have  the  responsibility  to  handle  the
knowledge of being at increased risk and passing this
information on to their relatives. They have to deal with
the knowledge of their genetic predisposition for the
rest of their lives. By being a mutation carrier they face
emotional as well as social problems that they must
share with their partners and children. Women with
positive BRCA test results are confronted with dilemmas
about their individual risk management: they have to
decide on preventive surgery, such as oophorectomy,
mastectomy and on breast reconstruction surgery. 
There is an immense psychological impact of these
decisions: dilemmas that are often underestimated in
the clinical situation when dealing with cancer risks are
the main objective. 
In  genetic  centres  and  family  clinics  in  the
Netherlands psychological support is generally offered
within a multi-disciplinary team as part of the entire
counselling procedure. But the Working Party explicitly
stresses the need for more research on the long-term
psychological  impact  of  these  dilemmas,  of
intervention surgery and of any kind of problems in the
society related to hereditary cancer. The Working Party
has suggested establishing a fixed programme of
psychological support that will take into consideration
the psychological difficulties that mutation carriers could
encounter after some time. 
K Kn no ow wl le ed dg ge e
In order to offer support and give information it is
essential for members of the Working Party to be
informed and keep themselves updated on all recent
developments. For that purpose, the professional
advisory members of the Working Party organise special
training courses and provide a direct communication
line if questions should be raised. The Working Party
also needs to be aware of new developments in society
and is actively involved in the debate on various ethical
issues related to hereditary aspects. 
I Is ss su ue es s   a at t   s st ta ak ke e   
I In ns su ur ra an nc ce e  d di is sc cr ri im mi in na at ti io on n
After DNA testing mutation carriers might encounter
genetic discrimination by insurance companies. If
mutation carriers in the Netherlands, both symptomatic
and asymptomatic, want more than very basic health
insurance, they could expect a rise in premiums if their
genetic predisposition to cancer is known. In the
application for life insurance – for instance for a
mortgage  or  disability  insurance,  the  insuranceH He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2004; 2(4) 201
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company is – according to specific criteria – allowed
to ask questions about hereditary diseases in the family.
The insurance company might then rise the premium
or could even refuse insurance.
These kinds of problems related to insurance
discrimination will have to be acknowledged and
anticipated and at the very least mentioned before
genetic testing. It is an alarming development if this
proved to be a strong deterrent for many people to
have a DNA test and it seems contradictory to all efforts
to detect healthy mutation carriers to reduce the
incidence  of  breast  and  ovarian  cancer  through
preventive health care.
The  Working  Party  keeps  in  touch  with  an
independent Help-Desk on insurance (“Het Breed
Platform Verzekerden”). They offer personal assistance
with insurance problems and keep records of all those
cases and incoming complaints. In this matter we also
intend to co-operate with other patient organisations
and alliances for hereditary diseases.
P Pa at te en nt ti in ng g  o of f  h hu um ma an n  g ge en ne es s
Recently the European Patent Office in Munich
revoked one of the patents on the BRCA genes
1. Four
patents were granted in the past few years to an
American  company.  European  legislation  (the
Directive on Biotechnological Inventions of 1998)
made it possible to patent isolated human genes and
“body parts” after they have been removed from their
natural surroundings.
The  opposition  against  the  patents  was
widespread in Europe. The BorstkankerVereniging
Nederland also supported this legal opposition raised
by genetic centres, laboratories and clinics from
several European countries, because it is feared that
the interests of potential mutation carriers could be
harmed by the patenting of the BRCA genes. 
Furthermore these patents cover the sequencing
of the BRCA genes, and somatic mutations to be
found in these genes associated with breast and
other  cancers.  This  could  prevent  any  further
development of research on these genes and might
also have a negative effect on the testing methods
(and availability and costs) of all European genetic
laboratories that perform the BRCA test.
The  revoking  of  the  patent  highlighted  this
controversial  situation  and  fortunately  the
international  debate  on  this  subject  has  lately
become even more widespread
2. Conferences and
workshops are organised to show many different
viewpoints on this controversial subject. The Working
Party actively participates in this debate.
P Pr re en na at ta al l  B BR RC CA A  t te es st ti in ng g
The breast and ovarian cancer susceptibility genes
are – at least in the Netherlands – often used as an
example in public debate on genetics and ethics in
general. One (controversial) example is the discussion
that with the knowledge of being a mutation carrier
some parents may consider the possibility of pregnancy
termination when a BRCA mutation is identified in the
foetus. The discussion whether genetic centres should
provide prenatal testing revolves around the ethics of
such a decision in relation to the risk, severity and
curability of the disease. The BRCA genes are again
given as an example, but in the future the discussion
could  also  become  relevant  in  relation  to  other
genetically predisposed diseases.
S St ta an nd da ar rd di is sa at ti io on n
The  Hamburg  conference  was  an  excellent
opportunity not only to illustrate the work of the
advocates for hereditary breast and ovarian cancer in
the Netherlands, but also show the international
relevance of the issues at stake. The Working Party aims
at more standardisation on surveillance and risk
management strategies for women at high risk, for
instance on preventive mastectomy. For example,
mastectomy followed by breast reconstruction surgery
is at the moment strongly advised to mutation carriers
by oncologists in all family clinics and university medical
centres in the Netherlands and Belgium, while in France
it is rarely done. 
The new Eusoma guidelines on the management
of familial breast cancer risk will be an important step
forward towards consensus in Europe. With these
European guidelines it might become more evident
what is generally considered as the best and safest
method of treatment and prevention for women at high
risk. Constant exchange and use of various data are
essential in these situations and we strongly advise the
participation from as many centres as possible that are
involved in hereditary breast/ovarian cancer syndromes.
The  preliminary  outlines  of  the  guidelines  as
presented in Hamburg revealed that women carriers
with a non-informative BRCA test result – the majority
of all women tested for BRCA1 and 2 – are excluded
from  preventive  mastectomy.  Maybe  clinics  and
oncologists  will  consider  offering  some  kind  of
mechanism to make preventive mastectomy possible
for these women, if mastectomy should be their explicit
choice of preventive strategy. Remembering that even
with a negative DNA test result on the breast/ovarian
cancer genes they are still at moderate to high risk toH He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2004; 2(4) 202
develop cancer, according to their family history, the
original reason to be tested.
The Working Party believes that we should all
benefit  from  the  exchange  of  data  and  the  co-
operation  between  institutions  and  clinics,
professionally as well as by patients and their families.
We could evaluate the outcome of risk management
strategies related to the quality of life, but also to the
incidence and mortality rates of breast and ovarian
cancer in general.
D DN NA A  u un ni it te ed d  f fo or rw wa ar rd d: :  a a  E Eu ur ro op pe ea an n  n ne et tw wo or rk k  o of f  g ge en ne et ti ic c
a ad dv vo oc ca at te es s! !
United co-operation among various disciplines was
the final slogan in my Hamburg patients’ point of view
on hereditary breast and ovarian cancer. It was also 
a direct call to launch a European genetic advocacy
network of BRCA gene mutation carriers, patients and
their families, starting with the Europa Donna network
of breast cancer advocates who were present at the
fourth  European  Breast  Cancer  Conference  in
Hamburg
3.
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